Showing results (51-60 of 119) with videos related to
Sort By:
Pageof 12
Cancer Biology & Therapy|December 28, 2017
Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemiaAnthony R Mato, Suparna Clasen, Peter Pickens, et al.Blood Advances|May 10, 2023
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemiaLindsey E Roeker, Maral DerSarkissian, Kellie Ryan, et al.Future Oncology (London, England)|September 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphomaChristine E Ryan, Matthew S Davids, Richard Hermann, et al.Investigational New Drugs|June 15, 2014
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patientsAjay K Gopal, Stefano R Tarantolo, Naresh Bellam, et al.Journal of Clinical Microbiology|March 8, 2005
Trends in drug resistance, serotypes, and molecular types of Streptococcus pneumoniae colonizing preschool-age children attending day care centers in Lisbon, Portugal: a summary of 4 years of annual surveillanceS Nunes, R Sá-Leão, J Carriço, et al.Critical Reviews in Oncology/Hematology|May 6, 2022
Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysisSarah Nocco, Tyler M Andriano, Arpita Bose, et al.Cancer Immunology Research|April 14, 2018
Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in MiceChih-Hang Tang, Shiun Chang, Ayumi Hashimoto, et al.Haematologica|December 17, 2020
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO studyAnthony R Mato, Jeff P Sharman, Juliana M L Biondo, et al.American Journal of Hematology|May 18, 2017
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysisSteven M Bair, Lauren Strelec, Sarah J Nagle, et al.Microbial Drug Resistance (Larchmont, N.Y.)|December 20, 2005
Natural history of drug-resistant clones of Streptococcus pneumoniae colonizing healthy children in PortugalR Mato, I Santos Sanches, C Simas, et al.Pageof 12